API-1 Akt Inhibitor Selective Kinase Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Akt pathway inhibitors face challenges such as toxicity and lack of selectivity, particularly in targeting hyperactivated Akt in cancer cells, leading to inadequate anti-tumor activity and adverse effects.
Innovation Solution
Development of a small molecule Akt pathway inhibitor, API-1, which selectively inhibits kinase activity and phosphorylation levels of Akt proteins without affecting upstream activators like PI3K and PDK1, thereby inducing apoptosis and cell growth arrest in cancer cells with elevated Akt levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If API-1 selectively inhibits Akt kinase activity in cancer cells with elevated Akt levels, then anti-tumor activity is improved, but selectivity and toxicity profile remain challenging
Solution Approach 1:
The compound API-1 exhibits differential inhibition based on local cellular context - it selectively inhibits Akt kinase activity in cells with elevated Akt levels (such as those with PTEN loss or Akt amplification) while having minimal effect on cells with normal Akt expression. This local quality approach allows the drug to target tumor cells specifically while sparing normal cells, thereby improving therapeutic index and reducing toxicity.
2Reliability
If Akt pathway inhibitors are developed to target hyperactivated Akt, then anti-tumor efficacy is improved, but selectivity between cancer cells and normal cells deteriorates
Solution Approach 1:
API-1 exploits the local quality difference in Akt activation status between cancer and normal cells. The compound preferentially binds to and inhibits the hyperactivated conformation of Akt found in malignant cells, while leaving the regulated, lower-level Akt activity in normal cells unaffected. This enables selective targeting of tumor cells based on their altered signaling state.
Solution Approach 2:
The inhibition of Akt by API-1 appears to be concentration-dependent and context-dependent. In cells with moderate Akt activation, partial inhibition may suffice to induce apoptosis, while in cells with very high Akt levels, the compound achieves near-complete inhibition. This partial or excessive action strategy allows the same compound to effectively target diverse tumor types with varying degrees of Akt hyperactivation.
Data Source
Figure 1A~1D
Figure 2A~2B
Figure 2C~2F
AI summary
The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering an effective amount of a compound of formula I to the person or animal.